Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 11/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 10/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.49 |
| ▸ | USP2 | O75604 | 5/20 | 0.49 |
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 6/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1707540 | 0.89 | LMNA (0.46) | LMNAMAPK1KDM4EHPGDEGFR | |
| SCHEMBL1707897 | 0.87 | ALDH1A1 (0.49) | CYP1A2CLK4CYP3A4USP2TSHR | |
| SCHEMBL1707572 | 0.87 | CYP1A2 (0.44) | CYP1A2CLK4CYP3A4USP2TSHR | |
| SCHEMBL1707310 | 0.86 | EGFR (0.42) | ALDH1A1LMNAMAPK1KDM4EHPGD | |
| SCHEMBL1707315 | 0.86 | GAA (0.43) | LMNAMAPK1KDM4EHPGDEGFR | |
| SCHEMBL1708349 | 0.84 | EGFR (0.39) | ALDH1A1LMNAMAPK1KDM4EHPGD | |
| SCHEMBL1706565 | 0.84 | EGFR (0.39) | ALDH1A1LMNAMAPK1KDM4EHPGD | |
| SCHEMBL2183102 | 0.83 | LMNA (0.47) | LMNAMAPK1KDM4EHPGDEGFR | |
| SCHEMBL1708357 | 0.83 | EGFR (0.38) | ALDH1A1LMNAMAPK1KDM4EHPGD | |
| SCHEMBL1706628 | 0.82 | EGFR (0.39) | CYP1A2HIF1AALDH1A1CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863283-B2 | Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2011-01-04 | — | — | US | claimed |
| EP-2247579-B1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | Bayer Pharma AG (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-7863283-B2 | Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2011-01-04 | — | — | US | disclosed |
| US-7863283-B2 | Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2011-01-04 | — | — | US | disclosed |
| US-7863283-B2 | Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2011-01-04 | — | — | US | disclosed |
| EP-2247579-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009089851-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-23 | — | — | WO | disclosed |
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | IFNG, TPMT, IRF3 | CYP1A2 757/4885CLK4 2909/4885CYP3A4 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.